Retrieve available abstracts of 19 articles: HTML format
Single Articles
May 2025
PAZ-ARES L, Borghaei H, Liu SV, Peters S, et al Efficacy and safety of first-line maintenance therapy with lurbinectedin plus
atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised,
multicentre, open-label, phase 3 trial.
Lancet. 2025 May 30:S0140-6736(25)01011-6. doi: 10.1016/S0140-6736(25)01011. PubMedAbstract available
March 2025
XIONG A, Wang L, Chen J, Wu L, et al Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer
(HARMONi-2): a randomised, double-blind, phase 3 study in China.
Lancet. 2025;405:839-849. PubMedAbstract available
September 2024
SPICER JD, Garassino MC, Wakelee H, Liberman M, et al Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab
compared with neoadjuvant chemotherapy alone in patients with early-stage
non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind,
placebo-controlled, phase 3
Lancet. 2024 Sep 12:S0140-6736(24)01756-2. doi: 10.1016/S0140-6736(24)01756. PubMedAbstract available
PRESLEY CJ, Owen DH Improved survival for patients with lung cancer treated with perioperative
immunotherapy.
Lancet. 2024 Sep 12:S0140-6736(24)01920-2. doi: 10.1016/S0140-6736(24)01920. PubMed
August 2024
MEYER ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, et al New promises and challenges in the treatment of advanced non-small-cell lung
cancer.
Lancet. 2024 Aug 6:S0140-6736(24)01029-8. doi: 10.1016/S0140-6736(24)01029. PubMedAbstract available
July 2024
CHANG JY, Verma V, Heymach JV Stereotactic ablative radiotherapy and immunotherapy for early-stage lung cancer
- Authors' reply.
Lancet. 2024;404:241-242. PubMed
HINDIE E Stereotactic ablative radiotherapy and immunotherapy for early-stage lung cancer.
Lancet. 2024;404:241. PubMed
JIANG L, Yu J, Meng X Stereotactic ablative radiotherapy and immunotherapy for early-stage lung cancer.
Lancet. 2024;404:240-241. PubMed
June 2024
THE LANCET Lung cancer treatment: 20 years of progress.
Lancet. 2024;403:2663. PubMed
May 2024
GIJTENBEEK RG, Noordhof AL, Asmara OD, Groen HJ, et al Immunotherapy in frail non-small-cell lung cancer patients.
Lancet. 2024;403:1986. PubMed
March 2024
MUROYA D, Morimitsu Y, Nakamura K, Hayashi K, et al Hidden metastatic lung tumour diagnosed by AI.
Lancet. 2024;403:1290. PubMed
EDERHY S, Cadranel J, Granger C, Hammoudi N, et al Investigation of endocarditis finds advanced lung adenocarcinoma: both resolve
after tyrosine kinase inhibitor treatment.
Lancet. 2024;403:860-861. PubMed
January 2024
PAZ-ARES L, Mehta B, Wang Y, Obiozor C, et al Sotorasib in KRAS(G12C) mutated lung cancer - Authors' reply.
Lancet. 2024;403:145-146. PubMed
OLIVIER T, Prasad V Sotorasib in KRAS(G12C) mutated lung cancer.
Lancet. 2024;403:145. PubMed
HANNA GG, McDonald F SBRT for oligoprogressive disease: using the evidence to maximise the benefits.
Lancet. 2024;403:122-124. PubMed
December 2023
CHU Q, Perrone F, Greillier L, Tu W, et al Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural
mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised
controlled trial.
Lancet. 2023;402:2295-2306. PubMedAbstract available
LEE YCG Pembrolizumab plus chemotherapy for pleural mesothelioma.
Lancet. 2023;402:2266-2267. PubMed
TSAI CJ, Yang JT, Shaverdian N, Patel J, et al Standard-of-care systemic therapy with or without stereotactic body radiotherapy
in patients with oligoprogressive breast cancer or non-small-cell lung cancer
(Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an
open-label, randomi
Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857. PubMedAbstract available
November 2023
SALMAN M, Fernandez Crespo R, Judah G Impact of messaging informed by behavioural science on uptake of targeted lung
health checks: a service evaluation.
Lancet. 2023;402 Suppl 1:S82. PubMedAbstract available